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Phenotype of p53 wild-type 
epitope-specific T cells in the 
circulation of patients with head 
and neck cancer
Andreas E. Albers  1, Xu Qian1, Andreas M. Kaufmann2, Daphne Mytilineos4, 
Robert L. Ferris3, Thomas K. Hoffmann4 & Albert B. DeLeo5,6
CD8+ cytotoxic T-cell (CTL) specific for non-mutated, wild type (wt) sequence p53 peptides derived 
from wt or mutant p53 molecules expressed in head and neck squamous cell carcinomas (HNSCC) 
have been detected in the circulation of patients with this disease. The frequency and differentiation/
maturation phenotypes of these anti-tumor specific CTL can reflect the host’s immunologic response. 
Therefore, we investigated the frequency and phenotypes of wt sequence p53 peptide-specific CTL 
in patients with HNSCC (n = 33) by flow cytometric analysis using HLA-A*0201 tetrameric peptides 
(tet) complexed with the wt sequence p53264–272 or p53149–157 peptide and co-staining with phenotypic 
markers. One main finding was that increasing frequencies of tet+ CD8+ T cells in patients’ circulation 
correlated with increased frequencies of inactive naïve tet+ cells, while those with effector memory 
and terminally differentiated phenotypes, which are associated with positive anti-tumor immune 
responses, decreased. We also found that the frequency of circulating tet+ CD8+ T cells negatively 
correlated with p53 expression in tumor tissues and tumor stage. Our findings support further clinical-
based investigations to define the frequencies and phenotypes of wt sequence p53 peptide-specific 
CD8+ T cells to predict disease severity, enhance selection of patients for inclusion in vaccination trials 
and highlight prerequisites to enhance immune susceptibility by activation of inactive naïve tet+ T cells 
and/or enhancing circulating effector T cell activity by checkpoint blockage.
The development and clinical application of novel biopharmaceutical agents targeting elements of the immune 
system, such as CTLA-4 and programmed death-1 (PD-1) checkpoint receptors as well as tumor associated cell 
surface antigens, has revolutionized immunotherapy and the oncologic treatment landscape. Patients with head 
and neck squamous cell carcinoma (HNSCC) are known to be immunosuppressed. Signaling defects in regulatory 
T cells (Treg) and cytolytic T lymphoctes (CTL) as well as a higher proportion of apoptotic T cells in these popula-
tions, in particular, anti-tumor specific CTL are detected in the peripheral blood of HNSCC patients compared to 
healthy individuals1–3. Thus, judiciously selected T-cell defined epitopes for cancer vaccines have been developed 
and defined with the aim to induce robust host anti-tumor immunogenicity. TP53, highly frequently mutated gene 
in HNSCC4, has been an attractive candidate for vaccines potentially capable of inducing immune responses in 
HNSCC patients directed against tumor-specific antigens. Mutant p53 protein, which accumulates in most HNSCC 
cells, potentially can yield mutation-specific p53 peptides. Although these epitopes would be tumor-specific, they 
have limited clinical applicability due primarily to the constraints imposed by antigen processing and presenta-
tion. In contrast, non-mutated, wild type (wt) sequence peptides derived from genetically altered p53 molecules 
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in tumors have a greater potential of being processed and presented and represent a more practical approach for 
developing broadly applicable p53-based cancer vaccines for the prevention and treatment of HNSCC5,6.
Previously, we have demonstrated in vitro that the presentation of wt sequence p53 peptides pulsed on 
autologous-derived dendritic cells (DC) induced peptide-specific immune responses from peripheral blood lym-
phocytes obtained from HLA-A2+ normal donors as well as patients with HNSCC7–10. Dendritic cells (DC)-based 
wt sequence p53 peptide vaccines have been used for immunotherapy in a variety of human cancers, including 
HNSCC. In a recent phase I clinical trial5 involving HLA-A2+ patients with HNSCC, patients were treated with 
a multiple CTL and T helper cell-defined, wt sequence p53 peptide-loaded DC-based adjuvant vaccination. The 
vaccination was shown to have some beneficial effects on the recipients. In patients with advanced HNSCC, 
however, there were limited post-vaccination anti-wt sequence p53 peptide-specific immunologic responses. 
Overall, wt sequence p53 peptide-specific CTL frequencies were increased post-vaccination in 69% of patients, 
with IFN-γ secretion detected in these cells in 25% of patients, but consistently decreased Treg frequencies rel-
ative to pre-vaccination values were also observed in these patients. However, disease free survival (DFS) after 
vaccination did not correlate with the presence or expression levels of p53 in the patients’ tumor cells nor with 
frequencies of wt sequence p53 peptide-specific CD8+ T cells in their peripheral circulation. Despite advances in 
the developing cancer vaccines, these findings are consistent with the poor clinical responses observed in many 
previous vaccine-based, cancer immunotherapy studies9,11.
To promote further understanding of the nature of wt p53 peptide-specific responses in patients with HNSCC 
and its relevance to patient survival and p53-based immunotherapy, it is important to determine the frequency 
and functional activity of wt sequence p53 peptide-specific CTL relative to their differentiation/maturation phe-
notype in these individuals. T cells have been characterized by their phenotypic and functional profiles into T 
cell subsets, namely, naïve (TN), central memory (TCM), effector memory (TEM) and terminally differentiated 
T cells (TTD). One established protocol for identifying these subsets is the differential expression of certain phe-
notypic markers, such as chemokine receptor 7 (CCR7) and CD45RA12,13. In addition, CTL function can also be 
assessed by monitoring IFNγ production and CD247/perforin expression. TN CD8+ T cells (CD45RA+CCR7+) 
are activated when interacting with antigen-presenting cells (APC) in secondary lymph nodes and rapidly 
proliferate and differentiate into TCM (CD45RA−CCR7+) and TEM (CD45RA−CCR7−). TEM migrate into 
the peripheral tissues and efficiently differentiate to effector cells TTD (CD45RA+CCR7−) while TCM home 
to the secondary lymphoid organs and retain the ability to proliferate and differentiate into TEM upon T cell 
receptor stimulation by antigen12. In this study, we determined the frequency and phenotype of wt sequence 
p53 peptide-specific T cells in the peripheral circulation of HLA-A*0201+ patients with HNSCC by multicolor 
flow cytometry using HLA-A*0201 tetramers (tet) complexed with wt sequence p53264–272 or p53149–157 peptides, 
referred to as tet264–272 and tet149–157, respectively. We further evaluated their correlation with clinicopathological 
factors as well as p53 and HPV status of the patients’ tumor specimens.
Methods
Ethics Statement and the criteria of patient inclusion. The clinical sample collection was carried out 
in accordance with the guidelines and protocols approved by the internal ethics board at University of Pittsburgh 
Cancer Institute (Pittsburgh, PA), and written informed consent was obtained from each participating individ-
ual prior to participation in the study. Patients with HNSCC (n = 33) were selected for inclusion into this study. 
None were receiving treatment at the time of blood draw. All blood samples were drawn pre-therapeutically 
after histological confirmation of HNSCC before removal of the cancers. All were HLA-A2+, as determined by 
sero-phenotyping of their peripheral blood mononuclear cells (PBMC) using monoclonal antibodies (mAbs) 
BB7.2 and MA2.1 (produced by hybridomas obtained from American Type Culture Collection, Manassas, VA)8. 
The clinicopathologic characteristics of the patients are listed in Table 1. TNM classification of malignant tumors 
according UICC 7th ed was used.
Collection of peripheral venous blood. Peripheral venous blood (30–50 mL) was drawn into heparinized 
tubes that were transferred to the laboratory and lymphocyte recovery on Ficoll-Hypaque gradients was immedi-
ately conducted. The recovered PBMC were washed, counted, and directly stained for ex vivo flow cytometry. The 
elapsed time between phlebotomy and PBMC staining for flow cytometry was within 2 hours.
Tetramers, antibodies and staining. The PE-labeled tet264–272 and tet149–157 reagents were obtained 
through the National Institute of Allergy and Infectious Diseases Tetramer Facility in Atlanta, GA. Titrations of 
tetramers and specificity assays were as follows: (a) all tetramers were pre-titered on bulk or cloned CD8+ T cell 
lines with specificity for the wt sequence p53 peptides were available in our laboratories to determine optimal 
reagent concentrations and to distinguish positive from negative signals; (b) negative controls were used with 
HLA-A2+ PBMC in all assays; (c) a cut-off for tetramer binding to PBMC of HLA-A2− normal donors (n = 10) 
was established as previously described by us1. The lower limit of detection (LLD) was defined as the frequency of 
1/7800 cells or approximately 0.01%. This LLD was used as a cut-off for evaluating all tetramer results presented 
in this manuscript.
The following anti-human mAbs were used in this study: CD8-PC5 (Beckman Coulter, Miami, FL), CD45RA-FITC 
(Immunotech), CCR7-PE and CD247-APC BD Biosciences perforin-FITC; BD Biosciences, San Jose, CA).
The staining for tetramers and cell surface antigens by flow cytometry was performed as previously described8. 
Briefly, for p53 tet, aliquots of diluted stock (1/100) of tet were added directly to subtly disrupted cell pellets at 
ambient temperature (5–7 × 106 cells). The cells were incubated for 30 minutes at room temperature in the dark. 
Next, 5 μl of each mAb was added on the cell subtlety disrupted pellet, followed by 30 minutes incubation at 4 °C 
in the dark. Cells were washed, centrifuged and resuspended in 500 μl of PBS/0.5% (wt/vol) paraformaldehyde. 
Flow cytometry was performed within 30 minutes.
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Immunohistochemistry. Immunostaining for p53 protein was performed as previously described9. Briefly, 
formalin-fixed, paraffin-embedded tissue specimens were sectioned (4 μm thick), deparaffinized and rehydrated 
in a series of graded ethanol. Immunohistochemical staining was performed using a mAb against p53 (DO-7, 
Dako, Carpinteria, CA, USA), which recognizes an epitope in the N-terminus between amino acid 35 and 45 
and reacts with the wt and most mutant forms of p53 protein, followed by the avidin-biotin-peroxidase method 
to visualize the p53 according to the manufacturer’s instructions (Dako). Positive and negative controls were 
included in each run for quality control of the immunoreactivity. IgG isotype mAb was used as a negative con-
trol. Normal-appearing salivary gland tissue or skeletal muscle from patients with HNSCC served as an internal 
non-tumor control. A tumor was considered p53 positive when >25% of the tumor cells showed staining inten-
sity of 2+ and higher on a scale of 0–4+. For p16 staining, mouse monoclonal antibody specific for p16 (1:100 
dilution, clone DCs-50; neomarkers, Fremont, CA, USA) was used as introduced before14. p16 expression was 
scored as positive if there was strong and diffuse nuclear and cytoplasmic staining in >60% of the tumor. Three 
independent experienced observers, who were blinded to the patient clinical information, performed semiquan-
titative evaluation of the slides.
Statistical analysis. The descriptive statistics were provided using the median/range and box plots. The 
associations among lymphocyte subsets were tested with the t test or Wilcoxon rank sum test (for two groups) or 
Kruscal Wallis test (for multiple groups). Reciprocal frequencies of tetramer counts were log transformed (base 














  <60 16 (48) 2 (29) 5 (63) 6 (50) 3 (50)
  ≥60 17 (52) 5 (71) 3 (37) 6 (50) 3 (50)
Gender
  Male 26 (79) 6 (86) 6 (75) 8 (67) 6 (100)
  Female 7 (21) 1 (14) 2 (25) 4 (33) 0 (0)
Primary tumor cite
  Oral cavity 7 (21) 1 (14) 1 (13) 4 (33) 1 (17)
  Oropharynx 16 (48) 4 (57) 5 (61) 4 (33) 3 (50)
  Larynx 6 (18) 2 (29) 1 (13) 1 (8) 2 (33)
  Others 4 (12) 0 (0) 1 (13) 3 (26) 0 (0)
Primary tumor stage*
  T1 15 (45) 5 (72) 4 (50) 2 (9) 4 (67)
  T2 7 (21) 1 (14) 2 (24) 2 (9) 2 (33)
  T3 8 (24) 1 (14) 1 (13) 6 (73) 0 (0)
  T4 3 (10) 0 (0) 1 (13) 2 (9) 0 (0)
Nodal status*
  N0 16 (48) 6 (86) 5 (63) 3 (26) 2 (33)
  N1 7 (21) 0 (0) 2 (25) 2 (9) 3 (50)
  N2 10 (30) 1 (14) 1 (12) 7 (65) 1 (17)
Tumor differentiation
  Well 5 (15) 1 (14) 2 (25) 1 (8) 1 (17)
  Moderate 24 (73) 6 (86) 6 (75) 9 (74) 3 (49)
  Poor 2 (6) 0 (0) 0 (0) 1 (8) 1 (17)
  Undifferentiated 2 (6) 0 (0) 0 (0) 1 (8) 1 (17)
Tumor p53 protein accumulation
  Positive 18 (55) 0 (0) 3 (37) 10 (83) 5 (83)
  Negative 15 (45) 7 (100) 5 (63) 2 (17) 1 (17)
p16 expression
  Positive 9 (27) 2 (29) 5 (63) 1 (8) 1 (17)
  Negative 24 (73) 5 (71) 3 (37) 11 (91) 5 (83)
Therapy
  Surgery only 18 (55) 6 (86) 4 (50) 4 (33) 4 (67)
  Surgery + radiation therapy 10 (30) 1 (14) 2 (25) 5 (42) 2 (33)
  Surgery + chemoradiotherapy 2 (15) 0 (0) 2 (25) 3 (25) 0 (0)
Table 1. Clinicopathologic characteristics and frequency of circulating wt p53-specific tet264–272+ CD8+ T 
cells in 33 patients with HNSCC who donated PBMC for this study. *TNM classification of malignant tumors 
according UICC 7th ed.
www.nature.com/scientificreports/
4SCIENtIFIC RepoRts |  (2018) 8:10716  | DOI:10.1038/s41598-018-29067-5
the relationship between the frequency of p53-specific CTL and clinicopathological parameters. All the reported 
p-values are based on two-sided tests.
Results
Frequencies of tet264–272+ and tet149–157+ CD8+ T cells in peripheral circulation of HLA-A0201+ 
patients with HNSCC. The frequencies of tet264–272+ CD8+ T cells in the peripheral circulation of 33 HLA-
A0201+ patients with HNSCC was determined by tetramer-based flow analysis, and in a similar manner, the 
frequency of tet149–157+ CD8+ T cells in samples obtained from 19 of these 33 patients. Based on the lower limit 
of detection (LLD) of 1/7800, 27/33 patients had detectable frequencies of tet264–272+ CD8+ T cells in their circu-
lation ranging from 1/7800 to 1/483, with an average frequency of 1/2694. Sufficient sample was obtained from 
19/33 patients, all of which had detectable levels of tet264–272+ CD8+ T cells for an additional analysis of tet149–157+ 
CD8+ T cells. These tet+CD8+ T cells were detectable at relatively high frequencies ranging from 1/4283 to 1/859 
in all 19 samples. In these 19 patients, the average frequency of tet264–272+ CD8+ T cells was 1/4707 (range 1/7798-
1/1239) and 1/2130 for tet149–157+ CD8+ T cells (range 1/5492–1/859). The reactivity with these two tetramers 
correlated (correlation: 0.636, p = 0.003, n = 19).
For further subgroup analysis, the frequencies of tet264–272+ and tet149–157+ CD8+ T cells detected in the periph-
eral circulation of patients with HNSCC were divided into 3 groups as follows: high frequency >1/2128; interme-
diate frequency <1/2128 but >1/4767; low frequency <1/4767. The distribution of high, intermediate and low 
frequency for each tet+CD8+ T cell specificity is listed in Table 2. In the group of tet264–272+CD8+ T cells, 6 cases 
were lower than 1/7800 cut off frequency. All frequencies of tet149–157+CD8+ T cells were higher than 1/7800.
Clinicopathological parameters and frequencies of tet264–272+ and tet149–157+ CD8+ T cells in 
peripheral circulation of patients with HNSCC. The distribution of high, intermediate and low fre-
quency for tet264–272+CD8+ T cells regarding to the clinicopathological parameters is listed in Table 1. Frequencies 
of tet264–272+CD8+ T cells tended to be higher in patients with T1 while those with low frequencies tended to be 
advanced T4 (Table 1). However, a significant inverse correlation between the frequency of tet264–272+CD8+ T 
cells and the tumor p53 accumulation (r = −0.637, p < 0.05) was noted with low T cell frequencies in the circu-
lation and a high p53 accumulation at the tumors site, strongly suggesting T cell depletion in patients with p53+ 
tumors. Similarly, a significant inverse correlation (r = −0.813, p < 0.05) was found between the frequency of 
tet149–157+CD8+ T cells and tumor p53 accumulation. There were no significant correlations between any of other 
clinical parameters listed in Table 2 and the frequencies of wt sequence p53 peptide-specific CD8+ T cells deter-
mined in the HNSCC patient’s samples (data not shown).
Disease-free survival relative to clinicopathology parameters and frequencies of tet264–272+ and 
tet149–157+CD8+ T cells in peripheral circulation of patients with HNSCC. Among the 33 patients, 
14 died of disease (DOD) and 1 died of unknown reason; 17 patients remain alive with no evidence of disease 
and 1 patient was alive with disease. The median follow-up was 8.82 years (range 2.33–23.42 years). Thus, 3-year 
DFS was 85% and 5-year DFS was 76% (Fig. 1A). No significant difference in DFS between patients who had p53+ 
versus p53− tumors was observed (Fig. 1B). As expected, HPV p16 status strongly predicted improved clinical 
outcome even within this small patient group (Fig. 1C). There was no significant difference of DFS, however, 
among patients who were stratified between those with no or low frequency of tet+ T cells and those with median 
or high frequency of tetramer reactive T cells (Fig. 1D).
Differentiation/maturation phenotypes of tet+CD8+ T cells and tet−CD8+ T cells in peripheral circu-
lation of patients with HNSCC. The tet+CD8+ T cells and tet−CD8+ T cells were co-stained for T cell surface 
marker expression CD45RA and CCR7 and analyzed by flow cytometry to determine their differentiation/maturation 
status as TN, TCM, TEM, and TTD. Representative dot plots obtained from one patient are shown in Fig. 2A.
As shown in Fig. 2B,C, the subpopulation of TN cells contained in both tet+ CD8+ T cell populations show a 
significant increase relative to the tet− CD8+ populations in the patients’ circulation. For tet264–272+CD8+ it was 
p < 0.001 and for tet149–156+CD8+ it was p = 0.005. In contrast, TEM tet+ CD8+ T cells for both specificities are 
significantly decreased when compared to the tet− population; tet264–272+CD8+ T cells it was p < 0.001 and for 
tet149–156+CD8+ T cells it was p = 0.001.
TD cell subpopulation was significantly decreased in tet264–272+CD8+ T cell population (p = 0.002) compared 
to the TD tet− subpopulation. There was no significant difference of TD tet+ CD8+ T cell subpopulations between 








>1/2128 7 (21.2) 7 (36.8)
Intermediate frequency
<1/2128 to > 1/4767 8 (24.2) 11 (57.9)
Low frequency
<1/4767 to > 1/7800 12 (36.4) 1 (5.3)
Negative
<1/7800 6 (18.2) 0 (0)
Table 2. Distribution of high, intermediate and low frequency for each tetramer+CD8+ T cell.
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Comparison of the percentages of the differentiation/maturation phenotypes of the tet264–272+ 
and tet149–157+ CD8+ T cell populations and tet− CD8+ T cell populations in patients’ peripheral 
circulation. The median percentages of the four differentiation/maturation phenotypes of tet264–272+ CD8+ 
T cells were compared to those of tet− CD8+ T cells relative to whether the patients’ peripheral circulation had 
high, medium, low, or no detectable levels of tet264–272+ CD8+ T cells in their circulation. The results of this anal-
ysis are presented in Table 3. Only in patients with high frequencies of tet264–272+ CD8+ T cells in their peripheral 
circulation were any significant differences detected: TN cells (CD45RA+/CCR7+) were significantly increased 
(p = 0.049), while TD cells (CD45RA+/CCR7−) were decreased (p = 0.022) (Table 3). No significant findings 
between phenotypes of tet149–157+CD8+ T cells and tet− CD8+ T cell populations were detected (data not shown).
Association between clinicopathological parameters and differentiation/maturation phenotypes 
of tet+264–272 CD8+ T cells. Possible associations between clinicopathological parameters and the mean per-
centage of tet264–272+ CD8+ T cells with different phenotypes detected in the peripheral blood of patients were also 
investigated (Table 4). A significantly (p = 0.029) lower mean percentage of tet 264–272+ TN CD8+ T cells was found 
in patients with T3–4 stage. In patients without p53 accumulation at the tumor sites, the percentage of tet 264–272+ 
CD8+ TD cells declined (p = 0.03) and a trend for increased TN cells (p = 0.06) was seen. No other significant 
findings relative to the other clinicopathological parameters studies.
Comparison of the differentiation phenotype (CD247/perforin) of tet274–272+ and tet149–156+ 
CD8+ T cells versus tet− CD8+ T cells. Sufficient cells were available from 20/33 patients for additional 
co-staining of CD8+ T cells with tet274–272 and CD247/perforin. The percentage of CD247+perforin+tet264–272+ 
CD8+ T cells was found to significantly decrease while that of CD247+perforin−tet264–272+CD8+ T cells 
Figure 1. Differential Phenotypes of wt sequence p53 peptide-specific tet+CD8+ and tet−CD8+ T cells in the 
peripheral circulation of patients with head and neck cancer. Examples of dot plots for patient #1 are shown for 
(A) CD45RA and CCR7 expression by wt sequence p53264–272-specific or wt sequence p53149-156-specific CD8+ T 
cells, and differentiation phenotypes of (B) wt sequence p53 tet264-272−CD8+ T cells and wt p53 tet264–272+CD8+ 
T cells (*p < 0.01), (C) wt sequence p53 tet149–156−CD8+ T cells and tet149–156+CD8+ T cells (*p < 0.01), and 
(D) CD247/Perforin expression of wt p53 tet264–272−CD8+ T cells and wt p53 tet264–272+CD8+ T cells (#p < 0.05; 
*p < 0.01).
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significantly increased when compared to the CD247+perforin+ tet− populations (Fig. 1D). Seven patients had 
increased CD247−/CD247+ ratio in perforin+tet264–272+CD8+ T cells (data not shown). CD247−perforin+tet264–272+ 
CD8+ T cells were not detected in 11 patients. Two patients had similar percentages of CD247−perforin+tet264–272+ 
CD8+ T cells as their tet− populations. Moreover, the percentage of CD247−perforin+tet264–272+CD8+ T cells was 
correlated to TD tet+ cells (p = 0.019). Samples from nine of 20 patients were also available for co-staining with 
p53149–156 tet and CD247/perforin. There were no significant differences in these populations in patients stained 
with tet149–156 (data not shown).
Figure 2. Disease-free survival (DFS) of patients with head and neck cancer. DFS was 85% after 3 years and 
76% after 5 years (A). DFS for patients based on p53 status (B), HPV p16 status (C) and the frequency of 











High frequency 7 76 (46–87) 10 (3–33) 12 (8–17) 2 (0–6)
Intermediate frequency 8 65 (44–91) 22 (3–50) 10 (0–25) 3 (0–7)
Low frequency 12 56 (25–76) 22 (5–35) 14 (0–27) 8 (2–25)
P = 0.049 P = 0.059 P = 0.338 P = 0.022
Tet264–272−CD8+
High frequency 7 38 (19–44) 40 (23–57) 11 (1–21) 10 (6–20)
Intermediate frequency 8 41 (23–55) 38 (22–50) 11 (3–17) 10 (4–22)
Low frequency 12 40 (7–68) 36 (17–65) 13 (3–32) 11 (4–24)
P = 0.933 P = 0.857 P = 0.917 P = 0.767
Table 3. Association of phenotypesa of wt p53-specific tet264–272+CD8+ or tet264–272−CD8+ T cells with 
frequencies (n = 27). aThe data are median percentages of positive cells among all tet+CD8+ T cells or all 
tet−CD8− T cells with the ranges in parentheses.
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Discussion
Wt sequence p53 tet+CD8+ T cells identified in patients with HNSCC. Consistent to our earlier 
findings and those of others9,15 tet264–272+ CD8+ T cells were identified in the circulation of most, but not all 
patients participating in this study. Furthermore, in patients who had tet264–272+ CD8+ T cells in their circulation, 
tet149–157+ CD8+ T cells were also detectable, indicative of a polyclonal reaction of T cells to this tumor antigen. 
The lack of a wt sequence p53 peptide immune response in some patients observed in this study has been noted 
in previous ones as well and may, in part, be due to the clonal deletion or anergy of effector T cells specific for self-
epitopes16 or apoptosis of T-cell receptor (TCR) variable β-chain-restricted antigen-responsive T cells17.
Differentiation/Maturation Phenotypic differences between tet+ and tet− CD8+ T cells in 
HNSCC patients’ circulation. In this study, we determined that in patients with a high frequency of tet+ 
CD8+ T cells in their peripheral circulation, tet+ cells with an N phenotype increased while those with the mature 
EM and TD phenotypes declined compared to those in the tet− populations. Previously, we have shown that tet+ 
CD8+ T cells in HNSCC patients preferentially localized to the tumor sites and tumor-involved lymph nodes and 
their frequencies increased in the population of tumor-infiltrating lymphocytes (TIL)8. Therefore, possible traf-
ficking of tet+CD8+ T cells with TD and EM phenotype to peripheral sites might alter the phenotype composition 
of these effectors in the circulation and enhance the N compartment.
CD247 or CD3-ζchain and perforin expression are widely used markers for T cell activation and the expression 
of perforin was found to decrease in CD247+ tet+CD8+ cells compared to CD247+ tet− CD8+ T cells. In addition, 
in some patients, tet+CD8+ T cells displayed a CD247− phenotype and a strong correlation with a TD phenotype 











<60 13 64 20.6 11.4 4
≥60 14 62.8 17.8 13.4 6.1
P = 0.9 P = 0.6 P = 0.5 P = 0.39
Gender
Male 20 63.6 19.5 12.4 4.4
Female 7 62.7 17.9 12.1 7.2
P = 0.9 P = 0.8 P = 0.9 P = 0.3
Primary tumor site
Oral cavity 7 62 19 15 4
Oropharynx 13 68 16 10 6
Larynx 4 69 18 12 1
Others 4 44 31 17 8
P = 0.12 P = 0.35 P = 0.38 P = 0.34
Primary tumor stage
T1–2 16 66.9 17.3 10.9 4.8
T3–4 11 58.2 21.7 14.5 5.7
P = 0.029 P = 0.45 P = 0.26 P = 0.5
Nodal status
N0 14 67 18 12 3
N1 4 58 24 15 3
N2 9 59 19 12 10
P = 0.47 P = 0.74 P = 0.76 P = 0.09
Tumor differentiation
Well 4 74 11 12 2.6
Moderate-poor 23 61 20.5 13 5.6
P = 0.2 P = 0.2 P = 0.9 P = 0.37
Tumor p53 protein accumulation
Positive 13 56.5 22.3 13.5 7.6
Negative 14 69.8 16 11.4 2.8
P = 0.06 P = 0.25 P = 0.47 P = 0.03
p16 expression
Positive 8 69.3 17 9.8 3.8
Negative 19 60.9 19.9 13.5 5.7
P = 0.28 P = 0.6 P = 0.25 P = 0.47
Table 4. Associations of clinicopathologic characteristics and phenotypes of circulating wt p53-specific tet264–272+ 
CD8+ T cells in 27 patients with HNSCC.
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peripheral sites in these patients concurrent with downregulation of CD247 expression8. A better 5-year survival 
has been shown in patients with tumors infiltrated by TILs expressing normal levels of CD3-ζchain than those 
showing loss of CD3-ζchain expression18,19. Although in the current study, CD247−perforin+tet+CD8+ T cells 
were not correlated to the low frequency tet+CD8+ T cells, it suggests that TD cells that traffic to the peripheral site 
lack T cell receptor-ζchain and may account for the unsuccessful or limited immune response in some patients.
Frequencies of circulating tet+CD8+ T cells negatively correlated to p53 expression in tumor 
tissues. In this study, patients who had high frequency of tet+ CD8+ T cells were found to have lower p53 
accumulations in their tumor tissues while patients with low frequency of tet+CD8+ T cells had higher p53 accu-
mulations in tumor tissues. This discrepancy is consistent with our previous finding relating frequencies of these 
tet+ CD8+ T cells in the peripheral circulation of HNSCC patients and p53 mutational sites in their tumors9 and 
suggests that these CTL in responsive patients could have eliminated tumor cells capable of processing and pre-
senting the targeted epitope resulting in the immunoselection and outgrowth of “epitope-loss” tumors.
Clinical relevance of circulating tet+ CD8+ T cells. The frequency of circulating tet+ CD8+ T cells was 
found to decrease in HNSCC patients with advanced disease. Furthermore, a decline of the N phenotype subpop-
ulation but similar TD phenotype subpopulation in tet+CD8+ T cells was found in advanced T stage as compared 
to lower T stage. The reason for this correlation remains presently unknown. As previously shown, the presence 
and frequency of tet+ CD8+ T cells among TIL did not correlate with tumor stage indicating it was independent of 
tumor progression in HNSCC8. We speculate that patients with advanced T stage HNSCC may not present the wt 
sequence p53 peptide epitopes properly or have limited CTL recognition due to the downregulation of expression 
of antigen-processing machinery components17,20. For example, CTL function may be suppressed by Treg, which 
are abundant in TIL at tumor sites8,21. Treg frequency, which is responsible for immunosuppression of adaptive 
and innate immunity and correlates with tumor progression and outcome, increases in patients with HNSCC8,22.
An important parameter that contributes to the complexity of analyzing immune responses of patients to 
HNSCC is HPV infection, since High Risk-HPV-related HNSCC currently accounts for 25% of HNSCC and 
up to 70% of oropharyngeal squamous carcinoma23. HPV E6 binds and degrades the p53 while E7 binds and 
degrades the pRB retinoblastoma tumor suppressor protein24. In HPV+ HNSCC, circulating HPV E7 specific 
CD8+ T cells are detectable indicating that endogenously-induced E7-specific immunity exists in these patients7. 
It has also been shown that wt and mutant p53 molecules are sensitive to HPV E6-mediated degradation and in 
vitro and in vivo results in increased presentation of the wt sequence p53264–272 peptide by HLA-A•0201+ tumors 
for CTL recognition6. Using p16 as the marker of HPV infection, there was no correlation of HPV expression 
in patients’ tumors to the frequencies of tet+ CD8+ T cells, in the patients’ circulation. However, consistent with 
current literature, p16 expression did correlate with improved DFS.
Relevant to the results of this study are the findings obtained from the recent multiepitope wt sequence p53 
peptide vaccine clinical trial5, the vaccination of patients with HNSCC resulted in an increased frequency of 
tet264–272+ CD8+ T cells in their peripheral circulation and decreased levels of Treg. Additionally, circulating tet+ 
CD8+ T cells were more vulnerable to spontaneous apoptosis suggesting their preferential demise represents a 
mechanism of immunoescape of tumor cells2. Nonetheless, these patients had a favorable two-year DFS of 88% as 
compared to 70% of DFS in a similar clinical trial cohort including unvaccinated patients treated with chemora-
diation25. Interestingly but unaccounted for at present, was that a limited and weak post-vaccination, wt sequence 
p53 peptide-specific immunity was observed in 5/16 patients. Overall, the presence or expression levels of p53 in 
these patients’ tumor tissues and the presence of tet+ CD8+ T cells in their peripheral blood after vaccination did 
not correlate to DFS. The explanation for this phenomenon is still unclear and requires a more extensive analysis 
of the nature of the immune response to wt sequence p53 peptide- specific epitopes in patients with HNSCC.
In perspective, our data support findings from the interaction of other solid cancers with the immune sys-
tem: presence of a range of tumor-specific T cells in various differentiation stages and an immunosuppressive 
tumor microenvironment on multiple levels8,26. With the advent of checkpoint inhibition treatment, it appears 
that tumor-specific T cells can be activated more readily and tumor immune suppression ameliorated to some 
extent. It will be intriguing to see if the empirically observed clinical benefit of checkpoint inhibitors27,28 can be 
explained by the use of our T cell characterization methods and that they could be used as a read out of patient 
response or selection for treatment.
In summary, the results of this study further revealed the complex nature of wt sequence p53 peptide-specific 
immune responses in HNSCC patients and highlight several new parameters, like naïve T cell activation by vac-
cination and checkpoint inhibition by modulating the PD-1/PD-L1 axis, that should be considered in developing 
the design and analysis of future vaccination protocols to enhance the efficacy of p53-based immunotherapy of 
HNSCC.
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